Adjuvant tyrosine kinase inhibitors plus anti-PD-1 therapy reduce recurrence in high-risk hepatocellular carcinoma after resection
Adjuvant TKIs combined with anti-PD-1 antibody significantly prolongs recurrence-free survival in HCC patients with high risk of postoperative recurrence. However, this combination does not confer a survival benefit in terms of overall survival. These findings support the potential clinical utility of adjuvant targeted immunotherapy in this high-risk population and highlight the need for further validation in prospective, randomized studies.
Authors
- Baomin Chen
- Zishun Liu (ORCID: https://orcid.org/0000-0003-4669-8347)
- Yali Gao (ORCID: https://orcid.org/0000-0002-5484-2559)
- Yukun Sun
- Yun Huang (ORCID: https://orcid.org/0000-0001-7200-5992)
- Jian Wu
- Jiaxin Li (ORCID: https://orcid.org/0000-0002-5401-6855)
- Qiang He (ORCID: https://orcid.org/0000-0002-5007-5225)
- Jianwen Huang (ORCID: https://orcid.org/0009-0002-0356-1930)
Institutions
- Sun Yat-sen University (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-11-13
- DOI
- https://doi.org/10.3389/fonc.2025.1710602
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00